Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS

Xing Zhang, Daria I. Vernikovskaya, Xiao-Ming Wang, Tatiana Nanovskaya, Maged Costantine, Gary Hankins, Mahmoud Ahmed

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

This report describes the development and validation of a chromatography/tandem mass spectrometry method for the quantitative determination of pravastatin and its metabolite (3α-hydroxy pravastatin) in plasma and urine of pregnant patients under treatment with pravastatin, as part of a clinical trial. The method includes a one-step sample preparation by liquid-liquid extraction. The extraction recovery of the analytes ranged between 93.8 and 99.5% in plasma. The lower limits of quantitation of the analytes in plasma samples were 0.106ng/mL for pravastatin and 0.105ng/mL for 3α-hydroxy pravastatin, while in urine samples they were 19.7ng/mL for pravastatin and 2.00ng/mL for 3α-hydroxy pravastatin. The relative deviation of this method was

Original languageEnglish (US)
Pages (from-to)548-554
Number of pages7
JournalBiomedical Chromatography
Volume30
Issue number4
DOIs
StatePublished - Apr 1 2016

Keywords

  • 3α-hydroxy pravastatin
  • LC-MS/MS
  • Metabolite
  • Pravastatin
  • Preeclampsia

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS'. Together they form a unique fingerprint.

  • Cite this